GlassScriptPhysician profile
Nicholas Thomson
NPI 1891106936
$21,248.53
in general payments reported to CMS, 2019-2025
70 companies · $3,762 in 2025
The $3,762 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $672 · 2021: $1,170 · 2022: $2,068 · 2023: $4,048 · 2024: $9,101 · 2025: $3,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,953 · Consulting Fee: $7,104 · Long Term Medical Supply Or Device Loan: $499 · Education: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,953.30 |
| Consulting Fee | $7,103.75 |
| Long Term Medical Supply Or Device Loan | $498.50 |
| Education | $355.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $6,735.42 | 2021-2025 | Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $1,515.02 | 2019-2025 | |
| Incyte Corporation | $1,278.55 | 2020-2025 | Jakafi, Niktimvo, Monjuvi |
| Pfizer INC. | $1,004.26 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $943.93 | 2020-2025 | Imfinzi, Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $719.19 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astellas Pharma US INC | $591.65 | 2020-2025 | Padcev, Xtandi, Vyloy |
| Emd Serono, INC. | $589.01 | 2020-2025 | Bavencio |
| Amgen INC. | $533.90 | 2020-2023 | Lumakras, Kyprolis, Xgeva |
| Lilly USA, LLC | $517.11 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $502.00 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $463.75 | 2022-2025 | Opdivo, Opdualag, Eliquis |
| Seagen INC. | $436.95 | 2019-2023 | Adcetris, Padcev |
| Janssen Biotech, INC. | $407.22 | 2021-2025 | Erleada, Darzalex, Talvey |
| Genzyme Corporation | $343.67 | 2021-2024 |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $297.90 | 2022-2025 | Reblozyl |
| Gilead Sciences, INC. | $274.20 | 2021-2025 | Trodelvy |
| Tersera Therapeutics LLC | $199.78 | 2021-2025 | Zoladex, Quzyttir |
| Bayer Healthcare Pharmaceuticals INC. | $195.87 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $191.72 | 2021-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $187.46 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Genentech USA, INC. | $173.58 | 2022-2025 | Itovebi, Polivy, Lunsumio |
| Dendreon Pharmaceuticals LLC | $165.47 | 2022-2025 | Provenge |
| Abbvie INC. | $164.67 | 2021-2025 | Venclexta |
| Array Biopharma INC | $161.91 | 2020-2025 | Braftovi, Mektovi, Tukysa |
| Sumitomo Pharma America, INC. | $153.81 | 2023-2025 | Orgovyx |
| Genmab U.S., INC. | $148.26 | 2023-2025 | Tivdak, Epkinly |
| Regeneron Healthcare Solutions, INC. | $134.68 | 2021-2024 | Libtayo |
| Puma Biotechnology, INC. | $127.68 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.01 | 2023-2025 | Fruzaqla |
| Pharmaessentia USA Corporation | $111.72 | 2023-2025 | Besremi |
| Sobi, INC | $110.16 | 2022-2025 | |
| Kite Pharma, INC. | $97.40 | 2022-2024 | Yescarta |
| Taiho Oncology, INC. | $80.90 | 2020-2021 | |
| Geron Corporation | $80.12 | 2025 | Rytelo |
| Coherus Oncology, INC. | $79.83 | 2022-2025 | Udenyca |
| Stemline Therapeutics INC. | $78.64 | 2023-2024 | Orserdu |
| Heron Therapeutics, INC. | $77.04 | 2020-2022 | |
| Rigel Pharmaceuticals, INC. | $75.33 | 2022-2024 | Rezlidhia, Tavalisse |
| Recordati_rare_diseases_inc. | $74.81 | 2023-2025 | Enjaymo, Sylvant |
| Kyowa Kirin, INC. | $69.94 | 2021 | |
| Karyopharm Therapeutics INC. | $66.58 | 2021-2023 | Xpovio |
| Agios Pharmaceuticals, INC. | $62.11 | 2022-2025 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $56.13 | 2021-2023 | Zepzelca |
| Pharmacosmos Therapeutics INC. | $55.32 | 2022-2025 | Monoferric |
| Mylan Institutional INC. | $55.09 | 2022-2023 | Ogivri, Fulphila |
| Deciphera Pharmaceuticals INC. | $54.62 | 2022-2025 | Qinlock, Tgct |
| Epizyme, INC. | $53.70 | 2021-2022 | |
| Foundation Medicine, INC. | $52.30 | 2022-2023 | |
| Exelixis INC. | $48.54 | 2024-2025 | Cabometyx |
| Pharming Healthcare, INC. | $44.05 | 2023-2024 | Ruconest |
| Azurity Pharmaceuticals, INC. | $41.07 | 2024-2025 | Danziten, Vivimusta |
| Cti Biopharma Corp. | $39.86 | 2022-2023 | Vonjo |
| Alexion Pharmaceuticals, INC. | $35.69 | 2019 | |
| Adc Therapeutics America, INC. | $34.36 | 2022-2023 | |
| Fennec Pharmaceuticals, INC. | $31.85 | 2023-2024 | Pedmark |
| Caris Mpi, INC. | $29.22 | 2025 | Mi Cancer Seek |
| Eusa Pharma (US) LLC | $28.56 | 2022 | |
| Amneal Pharmaceuticals LLC | $26.83 | 2023 | Neupogen, Avastin, Neulasta |
| Myriad Genetic Laboratories, INC. | $25.43 | 2024 | Myrisk |
| Servier Pharmaceuticals LLC | $23.14 | 2024 | |
| Pharmaand Gmbh | $23.03 | 2025 | Rubraca |
| Springworks Therapeutics, INC. | $22.52 | 2024 | Ogsiveo |
| Blueprint Medicines Corporation | $22.27 | 2023 | Ayvakit |
| Novocure INC. | $21.12 | 2023 | Optune |
| Secura Bio, INC. | $20.52 | 2021 | |
| Morphosys, US INC. | $17.59 | 2023 | Monjuvi |
| Novo Nordisk INC | $16.19 | 2020 | |
| Clovis Oncology, INC. | $15.47 | 2019 | |
| Medtronic, INC. | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Thomson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.